Overview

CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

To compare the Disease free survival (DFS) rate of a preoperative cetuximab treatment followed by operation and postoperative radiation-cisplatin-cetuximab treatment paradigm for advanced oral cavity cancer, , with the DFS rate of historical controls (from the RTOG 9501 and EORTC 22931 studies in which treatment was with surgery followed by radiotherapy and cisplatin) with a similar stage of the disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Rabin Medical Center

Collaborators:

Kaplan Medical Center
Meir Medical Center

Treatments:

Cetuximab